Home > News > Industry > Pharma News > Vineet Gupta appointed as...

Vineet Gupta appointed as GM of Eli Lilly India affiliate

By - Ruchika Sharma
Published On 2021-12-09 07:55 GMT   |   Update On 2021-12-09 07:55 GMT

New Delhi: Eli Lilly and company (India) has announced the appointment of Vineet Gupta as the General Manager of its India subsidiary with effect from 1 st January, 2022. Vineet will take over from Luca Visini who served as Managing Director of the company in India from February 2018 to December 2021.Vineet Gupta joined Eli Lilly in 2010 as Marketing Director for India, followed by a role...

Login or Register to read the full article
Register Now

New Delhi: Eli Lilly and company (India) has announced the appointment of Vineet Gupta as the General Manager of its India subsidiary with effect from 1 st January, 2022. Vineet will take over from Luca Visini who served as Managing Director of the company in India from February 2018 to December 2021.

Vineet Gupta joined Eli Lilly in 2010 as Marketing Director for India, followed by a role as Corporate Affairs & PRA (Pricing Reimbursement and Access) Director in 2012, and has since served in various strategic leadership roles across multiple countries including General Manager roles in Thailand, Philippines & Indonesia. He is currently based out of the Lilly Corporate Headquarters in Indianapolis (US).
Commenting on his return to India, Vineet Gupta said, "I am excited and honored to have this opportunity to lead the Eli Lilly India operations. I look forward to driving strategic business decisions that help us deliver on our promise of making life better for people around the world, and in India."
Luca Visini said, "I am incredibly grateful to have led a talented and dedicated team of professionals, all committed to our purpose in Lilly India. I am confident that with Vineet's leadership, Lilly India will continue to expand access to our innovative medicines for people who need them."

Eli Lilly and Company (India) Pvt. Ltd. (Lilly India), headquartered in Gurgaon, is a wholly owned subsidiary of Eli Lilly and Company, a global biopharmaceutical company headquartered in Indianapolis, USA.

Read also: Eli Lilly gets USFDA nod to Verzenio as adjuvant therapy for breast cancer patients

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

GSK raises USD 1.5 billion from sale of remaining Haleon stake
GSK Pharma declares financial results for quarter ended March 31, 2024
Use MvPI platform for reporting any adverse events linked to medical devices: CDSCO
CDSCO panel noted Biological E's Post Marketing Surveillance Report of Monovalent recombinant Hepatitis-B vaccine
Boehringer Ingelheim Spevigo injection for generalized pustular psoriasis flares gets CDSCO nod
Zydus Lifesciences appoints Shelina Parikh as Additional Director, Independent Director
Zydus Lifesciences arm, MSN Labs collaborate to license, supply cancer drug Cabozantinib in US
Dr Reddy's Labs gets 2 USFDA observations for Duvvada facilities